GlassScriptPhysician profile
Keith M Sieracki
NPI 1760436232
$6,931.85
in general payments reported to CMS, 2019-2025
29 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,328 · 2022: $1,134 · 2023: $1,626 · 2024: $1,545 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,469.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,079.56 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $1,016.72 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $737.66 | 2021-2025 | Verquvo |
| Pfizer INC. | $646.52 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $474.63 | 2022-2025 | Amvuttra, Onpattro |
| Astrazeneca Pharmaceuticals LP | $377.20 | 2021-2025 | Farxiga, Wainua, Andexxa |
| Amgen INC. | $295.03 | 2021-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $271.54 | 2022-2023 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $262.14 | 2023-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.26 | 2021-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $221.85 | 2021-2024 | |
| Esperion Therapeutics, INC. | $173.02 | 2021 | |
| Medtronic, INC. | $165.54 | 2022-2023 | Micra, Linq II |
| Janssen Pharmaceuticals, INC | $145.51 | 2021-2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $136.86 | 2024-2025 | Evkeeza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $99.76 | 2024 | Arcalyst |
| Abbott Laboratories | $95.30 | 2021-2024 | Aveir |
| Amarin Pharma, INC. | $73.79 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $69.77 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $67.34 | 2023-2024 | Opsumit, Uptravi |
| Bridgebio Pharma, INC. | $65.06 | 2025 | Attruby |
| Philips North America LLC | $47.54 | 2025 | Diagnostic Ecg Service, Extended Holter |
| Kiniksa Pharmaceuticals, LTD. | $44.35 | 2021-2023 | Arcalyst |
| Novo Nordisk INC | $43.56 | 2023-2024 | Ozempic, Rybelsus |
| Heartflow, INC. | $26.11 | 2025 | |
| Astellas Pharma US INC | $22.94 | 2023 | Veozah |
| Biosense Webster, INC. | $19.70 | 2025 | Nuvision Ice Catheter |
| Abiomed | $16.61 | 2023 | Impella |
| Sobi, INC | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Sieracki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.